Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus

Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (NASDAQ:MYL) and Biocon's Semglee, which is essentially identical to Sanofi's (NASDAQ:SNY) insulin product Lantus.